{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:40:41Z","timestamp":1793788841881,"version":"4.6.1"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00213-022-06123-7","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T06:57:41Z","timestamp":1648796261000},"page":"1989-2010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":228,"title":["Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-8530","authenticated-orcid":false,"given":"Jacob S.","family":"Aday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Heifets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Pratscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"6123_CR1","unstructured":"Aday JS (2021) Delineating the association between psychedelic drug use and facets of gratitude, aesthetic experience, and relationships with nature. Dissertation, Central Michigan University"},{"key":"6123_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","volume":"4","author":"JS Aday","year":"2021","unstructured":"Aday JS, Davis AK, Mitzkovitz CM, Bloesch EK, Davoli CC (2021) Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharm Trans Sci 4:424\u2013435. https:\/\/doi.org\/10.1021\/acsptsci.1c00014","journal-title":"ACS Pharm Trans Sci"},{"key":"6123_CR3","doi-asserted-by":"publisher","unstructured":"Aday JS, Bloesch EK, Davoli CC (2020a) 2019: A year of expansion in psychedelic research, industry, and deregulation. Drug Sci Pol Law 6. https:\/\/doi.org\/10.1177\/2050324520974484","DOI":"10.1177\/2050324520974484"},{"key":"6123_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","volume":"113","author":"JS Aday","year":"2020","unstructured":"Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK (2020b) Long-term effects of psychedelic drugs: a systematic review. Neurosci Biobehav Rev 113:179\u2013189. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.03.017","journal-title":"Neurosci Biobehav Rev"},{"key":"6123_CR5","doi-asserted-by":"publisher","unstructured":"Atlas LY (2021) A social affective neuroscience lens on placebo analgesia. Trends Cogn Sci. https:\/\/doi.org\/10.1016\/j.tics.2021.07.016","DOI":"10.1016\/j.tics.2021.07.016"},{"key":"6123_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/ije\/dyh299","volume":"34","author":"AG Barnett","year":"2005","unstructured":"Barnett AG, Van Der Pols JC, Dobson AJ (2005) Regression to the mean: what it is and how to deal with it. Int J Epidemiol 34:215\u2013220. https:\/\/doi.org\/10.1093\/ije\/dyh299","journal-title":"Int J Epidemiol"},{"key":"6123_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1176\/ajp.140.3.273","volume":"140","author":"AJ Barsky","year":"1983","unstructured":"Barsky AJ, Klerman GL (1983) Overview: hypochondriasis, bodily complaints, and somatic styles. Am J Psychiatry 140:273\u2013283. https:\/\/doi.org\/10.1176\/ajp.140.3.273","journal-title":"Am J Psychiatry"},{"key":"6123_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1001\/archpsyc.1997.01830200078011","volume":"54","author":"M Basoglu","year":"1997","unstructured":"Basoglu M, Marks I, Livanou M, Swinson R (1997) Double-blindness procedures, rater blindness, and ratings of outcome: observations from a controlled trial. Arch Gen Psychiatry 54:744\u2013748. https:\/\/doi.org\/10.1001\/archpsyc.1997.01830200078011","journal-title":"Arch Gen Psychiatry"},{"key":"6123_CR9","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.biopsych.2010.08.003","volume":"68","author":"G Bedi","year":"2010","unstructured":"Bedi G, Hyman D, de Wit H (2010) Is ecstasy an \u201cempathogen\u201d? Effects of\u00b13, 4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol Psychiatry 68:1134\u20131140. https:\/\/doi.org\/10.1016\/j.biopsych.2010.08.003","journal-title":"Biol Psychiatry"},{"key":"6123_CR10","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/s41386-019-0402-z","volume":"44","author":"AK Bershad","year":"2019","unstructured":"Bershad AK, Mayo LM, Van Hedger K, McGlone F, Walker SC, de Wit H (2019) Effects of MDMA on attention to positive social cues and pleasantness of affective touch. Neuropsychopharm 44:1698\u20131705. https:\/\/doi.org\/10.1038\/s41386-019-0402-z","journal-title":"Neuropsychopharm"},{"key":"6123_CR11","doi-asserted-by":"publisher","first-page":"70ra14-70ra14","DOI":"10.1126\/scitranslmed.3001244","volume":"3","author":"U Bingel","year":"2011","unstructured":"Bingel U, Wanigasekera V, Wiech K, Mhuircheartaigh RN, Lee MC, Ploner M, Tracey I (2011) The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci Transl Med 3:70ra14-70ra14. https:\/\/doi.org\/10.1126\/scitranslmed.3001244","journal-title":"Sci Transl Med"},{"key":"6123_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1080\/09593985.2018.1440676","volume":"35","author":"MD Bishop","year":"2019","unstructured":"Bishop MD, Mintken P, Bialosky JE, Cleland JA (2019) Factors shaping expectations for complete relief from symptoms during rehabilitation for patients with spine pain. Physiother Theory Prac 35:70\u201379. https:\/\/doi.org\/10.1080\/09593985.2018.1440676","journal-title":"Physiother Theory Prac"},{"key":"6123_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/bmj.309.6957.780","volume":"309","author":"JM Bland","year":"1994","unstructured":"Bland JM, Altman DG (1994) Statistics notes: some examples of regression towards the mean. BMJ 309:780. https:\/\/doi.org\/10.1136\/bmj.309.6957.780","journal-title":"BMJ"},{"key":"6123_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00213-013-3167-9","volume":"230","author":"JC Bouso","year":"2013","unstructured":"Bouso JC, F\u00e1bregas JM, Antonijoan RM, Rodr\u00edguez-Fornells A, Riba J (2013) Acute effects of ayahuasca on neuropsychological performance: differences in executive function between experienced and occasional users. Psychopharm 230:415\u2013424. https:\/\/doi.org\/10.1007\/s00213-013-3167-9","journal-title":"Psychopharm"},{"key":"6123_CR15","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1371\/journal.pmed.0030425","volume":"3","author":"I Boutron","year":"2006","unstructured":"Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hr\u00f3bjartsson A, Ravaud P (2006) Methods of blinding in reports of randomized controlled trials assessing pharmacologic treatments: a systematic review. PLoS Med 3:e425. https:\/\/doi.org\/10.1371\/journal.pmed.0030425","journal-title":"PLoS Med"},{"key":"6123_CR16","doi-asserted-by":"crossref","unstructured":"Burke MJ, Blumberger DM (2021) Caution at psychiatry\u2019s psychedelic frontier. Nat Med 27(10):1687\u20131688","DOI":"10.1038\/s41591-021-01524-1"},{"key":"6123_CR17","doi-asserted-by":"publisher","unstructured":"Burns JW, Jensen MP, Thorn BE, Lillis TA, Carmody J, Newman AK, Keefe F (2021) Cognitive therapy, mindfulness-based stress reduction, and behavior therapy for the treatment of chronic pain: a single-blind randomized controlled trial. Pain. https:\/\/doi.org\/10.1097\/j.pain.0000000000002357","DOI":"10.1097\/j.pain.0000000000002357"},{"key":"6123_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jama.2017.21903","volume":"319","author":"M Calvert","year":"2018","unstructured":"Calvert M, Kyte D, Mercieca-Bebber R et al (2018) Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA 319:483\u2013494. https:\/\/doi.org\/10.1001\/jama.2017.21903","journal-title":"JAMA"},{"key":"6123_CR19","doi-asserted-by":"publisher","unstructured":"Campbell CM, Gilron I, Doshi T, Raja S (2019) Designing and conducting proof-of-concept chronic pain analgesic clinical trials. Pain Rep 4. https:\/\/doi.org\/10.1097\/PR9.0000000000000697","DOI":"10.1097\/PR9.0000000000000697"},{"key":"6123_CR20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-017-4769-4","volume":"235","author":"TM Carbonaro","year":"2018","unstructured":"Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR (2018) Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharm 235:521\u2013534. https:\/\/doi.org\/10.1007\/s00213-017-4769-4","journal-title":"Psychopharm"},{"key":"6123_CR21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","volume":"232","author":"RL Carhart-Harris","year":"2015","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ (2015) LSD enhances suggestibility in healthy volunteers. Psychopharm 232:785\u2013794. https:\/\/doi.org\/10.1007\/s00213-014-3714-z","journal-title":"Psychopharm"},{"key":"6123_CR22","doi-asserted-by":"publisher","unstructured":"Carhart-Harris RL, Wagner AC, Agrawal M et al (2021) Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine? J Psychopharmacol. https:\/\/doi.org\/10.1177\/02698811211008567","DOI":"10.1177\/02698811211008567"},{"key":"6123_CR23","unstructured":"Carpenter DE (2020) 5-MeO-DMT: the 20-minute psychoactive toad experience that\u2019s transforming lives. Forbes. https:\/\/www.forbes.com\/sites\/davidcarpenter\/2020\/02\/02\/5-meo-dmt-the-20-minute-psychoactive-toad-experience-thats-transforming-lives\/?sh=293db2dd38a1"},{"key":"6123_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00213-009-1743-9","volume":"208","author":"B Colagiuri","year":"2010","unstructured":"Colagiuri B, Boakes RA (2010) Perceived treatment, feedback, and placebo effects in double-blind RCTs: an experimental analysis. Psychopharm 208:433\u2013441. https:\/\/doi.org\/10.1007\/s00213-009-1743-9","journal-title":"Psychopharm"},{"key":"6123_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1056\/NEJMra1907805","volume":"382","author":"L Colloca","year":"2020","unstructured":"Colloca L, Barsky AJ (2020) Placebo and nocebo effects. New Eng J Med 382:554\u2013561. https:\/\/doi.org\/10.1056\/NEJMra1907805","journal-title":"New Eng J Med"},{"key":"6123_CR26","doi-asserted-by":"publisher","unstructured":"Constantino MJ, Arnkoff DB, Glass CR, Ametrano RM, Smith JZ (2011) Expectations J Clin Psych, 67: 184\u2013192. https:\/\/doi.org\/10.1002\/jclp.20754","DOI":"10.1002\/jclp.20754"},{"key":"6123_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1037\/pst0000169","volume":"55","author":"MJ Constantino","year":"2018","unstructured":"Constantino MJ, V\u00eesl\u0103 A, Coyne AE, Boswell JF (2018) A meta-analysis of the association between patients\u2019 early treatment outcome expectation and their posttreatment outcomes. Psychother 55:473\u2013485. https:\/\/doi.org\/10.1037\/pst0000169","journal-title":"Psychother"},{"key":"6123_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-13-150","volume":"13","author":"JA Cunningham","year":"2013","unstructured":"Cunningham JA, Kypri K, McCambridge J (2013) Exploratory randomized controlled trial evaluating the impact of a waiting list control design. BMC Med Res Methodol 13:1\u20137. https:\/\/doi.org\/10.1186\/1471-2288-13-150","journal-title":"BMC Med Res Methodol"},{"key":"6123_CR29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1525\/nr.2020.24.1.31","volume":"24","author":"CM Cusack","year":"2020","unstructured":"Cusack CM (2020) Anne Hamilton-Byrne and the family: charisma, criminality, and media in the construction of an Australian \u201ccult\u201d leader. J Alt Emerg Rel 24:31\u201354. https:\/\/doi.org\/10.1525\/nr.2020.24.1.31","journal-title":"J Alt Emerg Rel"},{"key":"6123_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.annemergmed.2012.02.006","volume":"60","author":"G D\u2019Onofrio","year":"2012","unstructured":"D\u2019Onofrio G, Fiellin DA, Pantalon MV et al (2012) A brief intervention reduces hazardous and harmful drinking in emergency department patients. Ann Emerg Med 60:181\u2013192","journal-title":"Ann Emerg Med"},{"key":"6123_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psych 78:481\u2013489. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285","journal-title":"JAMA Psych"},{"key":"6123_CR32","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.biopsych.2021.01.016","volume":"89","author":"H de Wit","year":"2021","unstructured":"de Wit H, Bershad AK, Hutchison W et al (2021) Can MDMA change sociopolitical values? Insights from a research participant. Biol Psychiatry 89:e61\u2013e62. https:\/\/doi.org\/10.1016\/j.biopsych.2021.01.016","journal-title":"Biol Psychiatry"},{"key":"6123_CR33","doi-asserted-by":"crossref","unstructured":"Devilly GJ, Borkovec TD (2000) Psychometric properties of the credibility\/expectancy questionnaire. J Behav Ther Exp Psychiatry 31(2):73\u201386","DOI":"10.1016\/S0005-7916(00)00012-4"},{"key":"6123_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.psychres.2015.09.009","volume":"230","author":"D Dewey","year":"2015","unstructured":"Dewey D, McDonald MK, Brown WJ, Boyd SJ, Bunnell BE, Schuldberg D (2015) The impact of ecological momentary assessment on posttraumatic stress symptom trajectory. Psychiatry Res 230:300\u2013303. https:\/\/doi.org\/10.1016\/j.psychres.2015.09.009","journal-title":"Psychiatry Res"},{"key":"6123_CR35","doi-asserted-by":"crossref","unstructured":"Deyo RA, Dworkin SF, Amtmann D, Andersson G, Borenstein D et al (2014) Focus article: report of the NIH task force on research standards for chronic low back pain","DOI":"10.1097\/AJP.0000000000000120"},{"key":"6123_CR36","first-page":"1","volume":"23","author":"R Doblin","year":"1991","unstructured":"Doblin R (1991) Pahnke\u2019s \u201cGood Friday experiment\u201d: a long-term follow-up and methodological critique. J Transpers Psychol 23:1\u201328","journal-title":"J Transpers Psychol"},{"key":"6123_CR37","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-662-44519-8","volume-title":"Placebo Springer","author":"BK Doering","year":"2014","unstructured":"Doering BK, Rief W, Petrie KJ (2014) Lessons to be learned from placebo arms in psychopharmacology trials. In: Benedetti F, Enck P, Frisaldi E, Schedlowski M (eds) Placebo Springer. Heidelberg, Berlin, pp 273\u2013290. https:\/\/doi.org\/10.1007\/978-3-662-44519-8"},{"key":"6123_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-8-89","volume":"8","author":"LC Doward","year":"2010","unstructured":"Doward LC, Gnanasakthy A, Baker MG (2010) Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 8:1\u20139. https:\/\/doi.org\/10.1186\/1477-7525-8-89","journal-title":"Health Qual Life Outcomes"},{"key":"6123_CR39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.euroneuro.2010.09.004","volume":"21","author":"V Dragalin","year":"2011","unstructured":"Dragalin V (2011) An introduction to adaptive designs and adaptation in CNS trials. Euro Neuropsychopharm 21:153\u2013158. https:\/\/doi.org\/10.1016\/j.euroneuro.2010.09.004","journal-title":"Euro Neuropsychopharm"},{"key":"6123_CR40","unstructured":"Dupuis D (2021) Can psychedelics really change the world? Toward psychedelic technologies. MIND Foundation. https:\/\/mind-foundation.org\/psychedelic-technologies\/"},{"key":"6123_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.pain.2009.08.019","volume":"146","author":"RH Dworkin","year":"2009","unstructured":"Dworkin RH, Turk DC, McDermott MP et al (2009) Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 146:238\u2013244. https:\/\/doi.org\/10.1016\/j.pain.2009.08.019","journal-title":"Pain"},{"key":"6123_CR42","doi-asserted-by":"crossref","unstructured":"Dworkin RH, Turk DC, Peirce-Sandner S, et al. (2010) Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain 149:177\u2013193. \u200b\u200b10.1016\/j.pain.2010.02.018","DOI":"10.1016\/j.pain.2010.02.018"},{"key":"6123_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","volume":"9","author":"RH Dworkin","year":"2008","unstructured":"Dworkin RH, Turk DC, Wyrwich KW et al (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 9:105\u2013121. https:\/\/doi.org\/10.1016\/j.jpain.2007.09.005","journal-title":"J Pain"},{"key":"6123_CR44","doi-asserted-by":"publisher","unstructured":"Earleywine M, Ueno LF, Mian MN, Altman BR (2021) Cannabis-induced oceanic boundlessness. J Psychopharmacol. https:\/\/doi.org\/10.1177\/0269881121997099","DOI":"10.1177\/0269881121997099"},{"key":"6123_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-015-0531-9","volume":"15","author":"ER Eaves","year":"2015","unstructured":"Eaves ER, Sherman KJ, Ritenbaugh C, Hsu C, Nichter M, Turner JA, Cherkin DC (2015) A qualitative study of changes in expectations over time among patients with chronic low back pain seeking four CAM therapies. BMC Complement Altern Med 15:1\u201310. https:\/\/doi.org\/10.1186\/s12906-015-0531-9","journal-title":"BMC Complement Altern Med"},{"key":"6123_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.1997.10400190","volume":"29","author":"B Eisner","year":"1997","unstructured":"Eisner B (1997) Set, setting, and matrix. J Psychoactive Drugs 29:213\u2013216. https:\/\/doi.org\/10.1080\/02791072.1997.10400190","journal-title":"J Psychoactive Drugs"},{"key":"6123_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/nrd3923","volume":"12","author":"P Enck","year":"2013","unstructured":"Enck P, Bingel U, Schedlowski M et al (2013) The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 12:191\u2013204. https:\/\/doi.org\/10.1038\/nrd3923","journal-title":"Nat Rev Drug Discov"},{"key":"6123_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fpsyt.2019.00456","volume":"10","author":"P Enck","year":"2019","unstructured":"Enck P, Zipfel S (2019) Placebo effects in psychotherapy: a framework. Front Psychiatry 10:456. https:\/\/doi.org\/10.3389\/fpsyt.2019.00456","journal-title":"Front Psychiatry"},{"key":"6123_CR49","doi-asserted-by":"publisher","unstructured":"Erpelding N, Evans K, Lanier RK et al. (2020) Placebo response reduction and accurate pain reporting training reduces placebo responses in a clinical trial on chronic low back pain: results from a comparison to the literature. Clin J Pain 36:950\u2013954. https:\/\/doi.org\/10.1097\/AJP.0000000000000873","DOI":"10.1097\/AJP.0000000000000873"},{"key":"6123_CR50","doi-asserted-by":"publisher","first-page":"106503","DOI":"10.1016\/j.cct.2021.106503","volume":"107","author":"K Evans","year":"2021","unstructured":"Evans K, Colloca L, Pecina M et al (2021) What can be done to control the placebo response in clinical trials? A narrative review. Contemp Clin Trials 107:106503. https:\/\/doi.org\/10.1016\/j.cct.2021.106503","journal-title":"Contemp Clin Trials"},{"key":"6123_CR51","volume-title":"The psychedelic explorer\u2019s guide: safe, therapeutic, and sacred journeys","author":"J Fadiman","year":"2011","unstructured":"Fadiman J (2011) The psychedelic explorer\u2019s guide: safe, therapeutic, and sacred journeys. Simon and Schuster"},{"key":"6123_CR52","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.3899\/jrheum.100513","volume":"37","author":"R Ferrari","year":"2010","unstructured":"Ferrari R, Russell AS (2010) Effect of a symptom diary on symptom frequency and intensity in healthy subjects. J Rheumatol 37:2387\u20132389. https:\/\/doi.org\/10.3899\/jrheum.100513","journal-title":"J Rheumatol"},{"key":"6123_CR53","doi-asserted-by":"publisher","unstructured":"Fillingim RB, Price DD (2005) What is controlled for in placebo-controlled trials? In: Mayo Clinic Proceedings (Vol. 80, No. 9, pp. 1119\u20131121). Elsevier. https:\/\/doi.org\/10.4065\/80.9.1119","DOI":"10.4065\/80.9.1119"},{"key":"6123_CR54","doi-asserted-by":"publisher","unstructured":"Fisher S, Greenberg RP (1993) How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis. https:\/\/doi.org\/10.1097\/00005053-199306000-00002","DOI":"10.1097\/00005053-199306000-00002"},{"key":"6123_CR55","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/sim.5403","volume":"31","author":"TR Fleming","year":"2012","unstructured":"Fleming TR, Powers JH (2012) Biomarkers and surrogate endpoints in clinical trials. Stat Med 31:2973\u20132984. https:\/\/doi.org\/10.1002\/sim.5403","journal-title":"Stat Med"},{"key":"6123_CR56","doi-asserted-by":"crossref","unstructured":"Flowers EP, Freeman P, Gladwell VF (2018) Enhancing the acute psychological benefits of green exercise: An investigation of expectancy effects. Psychology of Sport and Exercise 39:213\u2013221","DOI":"10.1016\/j.psychsport.2018.08.014"},{"key":"6123_CR57","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1037\/hea0000867","volume":"39","author":"KE Freedland","year":"2020","unstructured":"Freedland KE (2020) Purpose-guided trial design in health-related behavioral intervention research. Health Psychol 39:539\u2013548. https:\/\/doi.org\/10.1037\/hea0000867","journal-title":"Health Psychol"},{"key":"6123_CR58","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/acps.12275","volume":"130","author":"TA Furukawa","year":"2014","unstructured":"Furukawa TA, Noma H, Caldwell DM et al (2014) Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 130:181\u2013192. https:\/\/doi.org\/10.1111\/acps.12275","journal-title":"Acta Psychiatr Scand"},{"key":"6123_CR59","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jpain.2019.12.003","volume":"21","author":"JS Gewandter","year":"2020","unstructured":"Gewandter JS, Dworkin RH, Turk DC et al (2020) Improving study conduct and data quality in clinical trials of chronic pain treatments: IMMPACT recommendations. J Pain 21:931\u2013942. https:\/\/doi.org\/10.1016\/j.jpain.2019.12.003","journal-title":"J Pain"},{"key":"6123_CR60","doi-asserted-by":"publisher","unstructured":"Glowacki DR, Wonnacott MD, Freire R et al (2020, April) Isness: using multi-person VR to design peak mystical type experiences comparable to psychedelics. In Proceedings of the 2020 CHI Conference on Human Factors in Computing Systems (pp. 1\u201314). https:\/\/doi.org\/10.1145\/3313831.3376649","DOI":"10.1145\/3313831.3376649"},{"key":"6123_CR61","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S2215-0366(17)30153-0","volume":"4","author":"SM Gold","year":"2017","unstructured":"Gold SM, Enck P, Hasselmann H et al (2017) Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. Lancet Psychiatry 4:725\u2013732. https:\/\/doi.org\/10.1016\/S2215-0366(17)30153-0","journal-title":"Lancet Psychiatry"},{"key":"6123_CR62","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30:1181\u20131197. https:\/\/doi.org\/10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"6123_CR63","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharma 187:268\u2013283. https:\/\/doi.org\/10.1007\/s00213-006-0457-5","journal-title":"Psychopharma"},{"key":"6123_CR64","doi-asserted-by":"crossref","unstructured":"Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.\u00a0 J Psychopharmacol 22(6):621\u2013632","DOI":"10.1177\/0269881108094300"},{"key":"6123_CR65","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71\u201378","journal-title":"Arch Gen Psychiatry"},{"key":"6123_CR66","doi-asserted-by":"publisher","unstructured":"Gukasyan N, Nayak SM (2021) Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy. Transcult Psych. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2010.116","DOI":"10.1001\/archgenpsychiatry.2010.116"},{"key":"6123_CR67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2018.00897","volume":"9","author":"ECHM Haijen","year":"2018","unstructured":"Haijen ECHM, Kaelen M, Roseman L et al (2018) Predicting responses to psychedelics: a prospective study. Front Pharmacol 9:897. https:\/\/doi.org\/10.3389\/fphar.2018.00897","journal-title":"Front Pharmacol"},{"key":"6123_CR68","volume-title":"American trip: set, setting, and the psychedelic experience in the twentieth century","author":"Hartogsohn","year":"2021","unstructured":"Hartogsohn (2021) American trip: set, setting, and the psychedelic experience in the twentieth century. The MIT Press, Cambridge"},{"key":"6123_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fnins.2018.00129","volume":"12","author":"I Hartogsohn","year":"2018","unstructured":"Hartogsohn I (2018) The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity. Front Neurosci 12:129. https:\/\/doi.org\/10.3389\/fnins.2018.00129","journal-title":"Front Neurosci"},{"key":"6123_CR70","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I (2016) Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol 30:1259\u20131267. https:\/\/doi.org\/10.1177\/0269881116677852","journal-title":"J Psychopharmacol"},{"key":"6123_CR71","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1136\/bmjebm-2019-111161","volume":"25","author":"MP Hengartner","year":"2020","unstructured":"Hengartner MP (2020) Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission. BMJ Evid Med 25:46\u201348. https:\/\/doi.org\/10.1136\/bmjebm-2019-111161","journal-title":"BMJ Evid Med"},{"key":"6123_CR72","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1001\/jamapsychiatry.2019.0766","volume":"76","author":"BD Heifets","year":"2019","unstructured":"Heifets BD, Williams NR, Bentzley BS, Schatzberg AF (2019) Rigorous trial design is essential to understand the role of opioid receptors in ketamine\u2019s antidepressant effect. JAMA Psych 76:657\u2013658. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.0766","journal-title":"JAMA Psych"},{"key":"6123_CR73","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/mp.2017.147","volume":"23","author":"F Hieronymus","year":"2018","unstructured":"Hieronymus F, Lisinski A, Nilsson S, Eriksson E (2018) Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Mol Psychiatry 23:1731\u20131736. https:\/\/doi.org\/10.1038\/mp.2017.147","journal-title":"Mol Psychiatry"},{"key":"6123_CR74","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343. https:\/\/doi.org\/10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"6123_CR75","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/cts.12255","volume":"8","author":"MB Holbein","year":"2015","unstructured":"Holbein MB, Berglund JP, Weatherwax K (2015) Access to investigational drugs: FDA expanded access programs or \u201cright to try\u201d legislation? Clin Transl Sci 8:526\u2013532. https:\/\/doi.org\/10.1111\/cts.12255","journal-title":"Clin Transl Sci"},{"key":"6123_CR76","doi-asserted-by":"publisher","unstructured":"Horton DM, Morrison B, Schmidt J (2021) Systematized review of psychotherapeutic components of psilocybin-assisted psychotherapy. Amer J Psychother. https:\/\/doi.org\/10.1176\/appi.psychotherapy.20200055","DOI":"10.1176\/appi.psychotherapy.20200055"},{"key":"6123_CR77","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1037\/a0022186","volume":"48","author":"AO Horvath","year":"2011","unstructured":"Horvath AO, Del Re AC, Fl\u00fcckiger C, Symonds D (2011) Alliance in individual psychotherapy. Psychother 48:9\u201316. https:\/\/doi.org\/10.1037\/a0022186","journal-title":"Psychother"},{"key":"6123_CR78","doi-asserted-by":"publisher","unstructured":"Hr\u00f3bjartsson A, G\u00f8tzsche PC (2010) Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003974.pub3","DOI":"10.1002\/14651858.CD003974.pub3"},{"key":"6123_CR79","doi-asserted-by":"publisher","first-page":"e1119","DOI":"10.1136\/bmj.e1119","volume":"344","author":"A Hr\u00f3bjartsson","year":"2012","unstructured":"Hr\u00f3bjartsson A, Thomsen ASS, Emanuelsson F, Tendal B, Hilden J, Boutron I, Ravaud P, Brorson S (2012) Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. BMJ 344:e1119. https:\/\/doi.org\/10.1136\/bmj.e1119","journal-title":"BMJ"},{"key":"6123_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10543406.2015.1092028","volume":"26","author":"A Ivanova","year":"2016","unstructured":"Ivanova A, Zhang Z, Thompson L, Yang Y, Kotz RM, Fang X (2016) Can sequential parallel comparison design and two-way enriched design be useful in medical device clinical trials? J Biopharm Stat 26:167\u2013177. https:\/\/doi.org\/10.1080\/10543406.2015.1092028","journal-title":"J Biopharm Stat"},{"key":"6123_CR81","doi-asserted-by":"crossref","unstructured":"Johnson MW, Griffiths RR (2017) Potential therapeutic effects of psilocybin. Neurotherapeutics 14(3):734\u2013740","DOI":"10.1007\/s13311-017-0542-y"},{"key":"6123_CR82","doi-asserted-by":"crossref","unstructured":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol 28(11):983\u2013992","DOI":"10.1177\/0269881114548296"},{"key":"6123_CR83","doi-asserted-by":"publisher","first-page":"e2125531","DOI":"10.1001\/jamanetworkopen.2021.25531","volume":"4","author":"BDM Jones","year":"2021","unstructured":"Jones BDM, Razza LB, Weissman CR et al (2021) Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open 4:e2125531. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.25531","journal-title":"JAMA Netw Open"},{"key":"6123_CR84","doi-asserted-by":"publisher","unstructured":"Juul S, Gluud C\ufeff, Simonsen S\ufeff, Frandsen FW\ufeff, Kirsch I\ufeff, Jakobsen JC\ufeff (2020) Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports. BMJ Evid Based Med https:\/\/doi.org\/10.1136\/bmjebm-2020-111407","DOI":"10.1136\/bmjebm-2020-111407"},{"key":"6123_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81446-7","volume":"11","author":"LS Kaertner","year":"2021","unstructured":"Kaertner LS, Steinborn MB, Kettner H et al (2021) Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing. Sci Rep 11:1\u201311. https:\/\/doi.org\/10.1038\/s41598-021-81446-7","journal-title":"Sci Rep"},{"key":"6123_CR86","doi-asserted-by":"publisher","unstructured":"Kaptchuk TJ, Hemond CC, Miller FG (2020) Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice. BMJ 370. https:\/\/doi.org\/10.1136\/bmj.m1668","DOI":"10.1136\/bmj.m1668"},{"key":"6123_CR87","doi-asserted-by":"publisher","unstructured":"Katz N (2021) Design and conduct of confirmatory chronic pain clinical trials. Pain Reports 6. https:\/\/doi.org\/10.1097\/PR9.0000000000000854","DOI":"10.1097\/PR9.0000000000000854"},{"key":"6123_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JCP.0b013e31802eb4b7","volume":"27","author":"KA Kobak","year":"2007","unstructured":"Kobak KA, Kane JM, Thase ME et al (2007) Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 27:1\u20135. https:\/\/doi.org\/10.1097\/JCP.0b013e31802eb4b7","journal-title":"J Clin Psychopharmacol"},{"key":"6123_CR89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/03060497.2003.11086195","volume":"42","author":"Y Kogo","year":"2002","unstructured":"Kogo Y (2002) Aum Shinrikyo and spiritual emergency. J Humanist Psychol 42:82\u2013101. https:\/\/doi.org\/10.1080\/03060497.2003.11086195","journal-title":"J Humanist Psychol"},{"key":"6123_CR90","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1600-0528.2009.00494.x","volume":"37","author":"J Kolahi","year":"2009","unstructured":"Kolahi J, Bang H, Park J (2009) Towards a proposal for assessment of blinding success in clinical trials: up to date review. Comm Dent Oral Epidem 37:477\u2013484. https:\/\/doi.org\/10.1111\/j.1600-0528.2009.00494.x","journal-title":"Comm Dent Oral Epidem"},{"key":"6123_CR91","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.drudis.2016.11.022","volume":"22","author":"T Kube","year":"2017","unstructured":"Kube T, Rief W (2017) Are placebo and drug-specific effects additive? Questioning basic assumptions of double-blinded randomized clinical trials and presenting novel study designs. Drug Discov Today 22:729\u2013735. https:\/\/doi.org\/10.1016\/j.drudis.2016.11.022","journal-title":"Drug Discov Today"},{"key":"6123_CR92","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1177\/0269881119857204","volume":"33","author":"KP Kuypers","year":"2019","unstructured":"Kuypers KP, Ng L, Erritzoe D et al (2019) Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. J Psychopharmacol 33:1039\u20131057. https:\/\/doi.org\/10.1177\/0269881119857204","journal-title":"J Psychopharmacol"},{"key":"6123_CR93","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3389\/fpsyg.2017.00233","volume":"8","author":"JAC Laferton","year":"2017","unstructured":"Laferton JAC, Kube T, Salzmann S, Auer CJ, Shedden-Mora MC (2017) Patients\u2019 expectations regarding medical treatment: a critical review of concepts and their assessment. Front Psychol 8:233. https:\/\/doi.org\/10.3389\/fpsyg.2017.00233","journal-title":"Front Psychol"},{"key":"6123_CR94","unstructured":"Leake GJ, King AS (1977) Effect of counsellor expectation on alcoholic recovery. Alcohol, Health, and Research Work 11(16)"},{"key":"6123_CR95","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00005053-196312000-00007","volume":"137","author":"T Leary","year":"1963","unstructured":"Leary T, Litwin GH, Metzner R (1963) Reactions to psilocybin administered in a supportive environment. J Nerv Ment Dis 137:561\u2013573. https:\/\/doi.org\/10.1097\/00005053-196312000-00007","journal-title":"J Nerv Ment Dis"},{"key":"6123_CR96","unstructured":"Ledford JA (2019) Sex, drugs, and mind control: Tom O\u2019Neill, with Dan Pipenbring: Chaos: Charles Manson, the CIA, and the Secret History of the Sixties Little, Brown and Company, New York"},{"key":"6123_CR97","doi-asserted-by":"publisher","unstructured":"Leger RF, Unterwald EM (2021) Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis. J Psychopharmacol. https:\/\/doi.org\/10.1177\/02698811211044688","DOI":"10.1177\/02698811211044688"},{"key":"6123_CR98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1037\/cns0000105","volume":"4","author":"SJ Lynn","year":"2017","unstructured":"Lynn SJ, Evans J (2017) Hypnotic suggestion produces mystical-type experiences in the laboratory: a demonstration proof. Psych Conscious: Theory Res Prac 4:23\u201337. https:\/\/doi.org\/10.1037\/cns0000105","journal-title":"Psych Conscious: Theory Res Prac"},{"key":"6123_CR99","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","volume":"51","author":"KA MacLean","year":"2012","unstructured":"MacLean KA, Leoutsakos JM, Johnson MW, Griffiths RR (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51:721\u2013737. https:\/\/doi.org\/10.1111\/j.1468-5906.2012.01685.x","journal-title":"J Sci Study Relig"},{"key":"6123_CR100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0269881114568040","volume":"29","author":"T Maji\u0107","year":"2015","unstructured":"Maji\u0107 T, Schmidt TT, Gallinat J (2015) Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? J Psychopharmacol 29:241\u2013253. https:\/\/doi.org\/10.1177\/0269881114568040","journal-title":"J Psychopharmacol"},{"key":"6123_CR101","doi-asserted-by":"publisher","unstructured":"Marks M, Cohen IG (2021) Psychedelic therapy: a roadmap for wider acceptance and utilization. Nat Med. https:\/\/doi.org\/10.1038\/s41591-021-01530-3","DOI":"10.1038\/s41591-021-01530-3"},{"key":"6123_CR102","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","volume":"85","author":"T Marton","year":"2019","unstructured":"Marton T, Barnes DE, Wallace A, Woolley JD (2019) Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity. Biological Psych 85:e75\u2013e76. https:\/\/doi.org\/10.1016\/j.biopsych.2019.02.008","journal-title":"Biological Psych"},{"key":"6123_CR103","doi-asserted-by":"publisher","unstructured":"Mataix-Cols D, Andersson E (2021) Ten practical recommendations for improving blinding integrity and reporting in psychotherapy trials. JAMA Psych. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.1419","DOI":"10.1001\/jamapsychiatry.2021.1419"},{"key":"6123_CR104","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jclinepi.2014.02.001","volume":"67","author":"E Mathieu","year":"2014","unstructured":"Mathieu E, Herbert RD, McGeechan K, Herbert JJ, Barratt AL (2014) A theoretical analysis showed that blinding cannot eliminate potential for bias associated with beliefs about allocation in randomized clinical trials. J Clin Epidemiol 67:667\u2013671. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.02.001","journal-title":"J Clin Epidemiol"},{"key":"6123_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-7-30","volume":"7","author":"R McCarney","year":"2007","unstructured":"McCarney R, Warner J, Iliffe S et al (2007) The Hawthorne effect: a randomised, controlled trial. BMC Med Res Methodol 7:1\u20138. https:\/\/doi.org\/10.1186\/1471-2288-7-30","journal-title":"BMC Med Res Methodol"},{"key":"6123_CR106","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/10.2147\/PROM.S156279","volume":"9","author":"R Mercieca-Bebber","year":"2018","unstructured":"Mercieca-Bebber R, King MT, Calvert MJ et al (2018) The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas 9:353. https:\/\/doi.org\/10.1186\/10.2147\/PROM.S156279","journal-title":"Patient Relat Outcome Meas"},{"key":"6123_CR107","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1371\/journal.pmed.0020262","volume":"2","author":"FG Miller","year":"2005","unstructured":"Miller FG, Wendler D, Swartzman LC (2005) Deception in research on the placebo effect. PLoS Med 2:e262. https:\/\/doi.org\/10.1371\/journal.pmed.0020262","journal-title":"PLoS Med"},{"key":"6123_CR108","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L et al (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharm 236:2735\u20132745. https:\/\/doi.org\/10.1007\/s00213-019-05249-5","journal-title":"Psychopharm"},{"key":"6123_CR109","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1056\/NEJMoa013259","volume":"347","author":"JB Moseley","year":"2002","unstructured":"Moseley JB, O\u2019Malley K, Petersen NJ et al (2002) A controlled trial of arthroscopic surgery for osteoarthritis of the knee. NE J Med 347:81\u201388. https:\/\/doi.org\/10.1056\/NEJMoa013259","journal-title":"NE J Med"},{"key":"6123_CR110","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s12160-016-9854-0","volume":"51","author":"JM Mundt","year":"2017","unstructured":"Mundt JM, Roditi D, Robinson ME (2017) A comparison of deceptive and non-deceptive placebo analgesia: efficacy and ethical consequences. Ann Behav Med 51:307\u2013315. https:\/\/doi.org\/10.1007\/s12160-016-9854-0","journal-title":"Ann Behav Med"},{"key":"6123_CR111","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00213-019-05445-3","volume":"237","author":"A Murphy-Beiner","year":"2020","unstructured":"Murphy-Beiner A, Soar K (2020) Ayahuasca\u2019s \u2018afterglow\u2019: improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharm 237:1161\u20131169. https:\/\/doi.org\/10.1007\/s00213-019-05445-3","journal-title":"Psychopharm"},{"key":"6123_CR112","doi-asserted-by":"publisher","unstructured":"Muthukumaraswamy S, Forsyth A, Lumley T (2021) Blinding and expectancy confounds in psychedelic randomised controlled trials. Expert Rev Clin Pharmacol. https:\/\/doi.org\/10.1080\/17512433.2021.1933434","DOI":"10.1080\/17512433.2021.1933434"},{"key":"6123_CR113","doi-asserted-by":"publisher","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (\u00b13, 4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharm 27:40\u201352. https:\/\/doi.org\/10.1177\/0269881112464827","DOI":"10.1177\/0269881112464827"},{"key":"6123_CR114","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","volume":"4","author":"DE Olson","year":"2020","unstructured":"Olson DE (2020) The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharm Trans Sci 4:563\u2013567. https:\/\/doi.org\/10.1021\/acsptsci.0c00192","journal-title":"ACS Pharm Trans Sci"},{"key":"6123_CR115","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00213-020-05464-5","volume":"237","author":"JA Olson","year":"2020","unstructured":"Olson JA, Suissa-Rocheleau L, Lifshitz M et al (2020) Tripping on nothing: placebo psychedelics and contextual factors. Psychopharm 237:1371\u20131382. https:\/\/doi.org\/10.1007\/s00213-020-05464-5","journal-title":"Psychopharm"},{"key":"6123_CR116","doi-asserted-by":"crossref","unstructured":"Pace BA, Devenot N (2021) Right-wing psychedelia: case studies in cultural plasticity and political pluripotency. Front Psychol","DOI":"10.3389\/fpsyg.2021.733185"},{"key":"6123_CR117","volume-title":"Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness","author":"WN Pahnke","year":"1963","unstructured":"Pahnke WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and the mystical consciousness: a thesis. Dissertation. Harvard University"},{"key":"6123_CR118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B et al (2018) Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med 16:1\u201315. https:\/\/doi.org\/10.1186\/s12916-018-1017-7","journal-title":"BMC Med"},{"key":"6123_CR119","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpsychires.2016.08.015","volume":"83","author":"B Patterson","year":"2016","unstructured":"Patterson B, Boyle MH, Kivlenieks M, Van Ameringen M (2016) The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res 83:112\u2013120. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.08.015","journal-title":"J Psychiatr Res"},{"key":"6123_CR120","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamapsychiatry.2015.1335","volume":"72","author":"M Peci\u00f1a","year":"2015","unstructured":"Peci\u00f1a M, Bohnert AS, Sikora M, Avery ET, Langenecker SA, Mickey BJ, Zubieta JK (2015) Association between placebo-activated neural systems and antidepressant responses: neurochemistry of placebo effects in major depression. JAMA Psych 72:1087\u20131094. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.1335","journal-title":"JAMA Psych"},{"key":"6123_CR121","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/mp.2014.164","volume":"20","author":"M Peci\u00f1a","year":"2013","unstructured":"Peci\u00f1a M, Zubieta JK (2013) Molecular mechanisms of placebo responses in humans. Mol Psychiatry 20:416\u2013423. https:\/\/doi.org\/10.1038\/mp.2014.164","journal-title":"Mol Psychiatry"},{"key":"6123_CR122","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/0886260513505705","volume":"29","author":"ER Pedersen","year":"2014","unstructured":"Pedersen ER, Kaysen DL, Lindgren KP, Blayney J, Simpson TL (2014) Impact of daily assessments on distress and PTSD symptoms in trauma-exposed women. J Interpers Violence 29:824\u2013845. https:\/\/doi.org\/10.1177\/0886260513505705","journal-title":"J Interpers Violence"},{"key":"6123_CR123","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M (2016) The nocebo effect of drugs. Pharmacol Res Perspect 4:e00208. https:\/\/doi.org\/10.1002\/prp2.208","journal-title":"Pharmacol Res Perspect"},{"key":"6123_CR124","volume-title":"How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, and addiction","author":"M Pollan","year":"2018","unstructured":"Pollan M (2018) How to change your mind: what the new science of psychedelics teaches us about consciousness, dying, and addiction. Penguin, New York"},{"key":"6123_CR125","unstructured":"Prideaux, E. (2021). The worldview-changing drugs poised to go mainstream. BBCpage. https:\/\/www.bbc.com\/future\/article\/20210906-what-if-everyone-took-psychedelics"},{"key":"6123_CR126","first-page":"40","volume":"6","author":"I Puente","year":"2014","unstructured":"Puente I (2014) Holotropic breathwork can occasion mystical experiences in the context of a daylong workshop. J Transper Res 6:40\u201350","journal-title":"J Transper Res"},{"key":"6123_CR127","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0165-1781(86)90094-6","volume":"19","author":"JG Rabkin","year":"1986","unstructured":"Rabkin JG, Markowitz JS, Stewart JW et al (1986) How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 19:75\u201386. https:\/\/doi.org\/10.1016\/0165-1781(86)90094-6","journal-title":"Psychiatry Res"},{"key":"6123_CR128","doi-asserted-by":"publisher","first-page":"760671","DOI":"10.3389\/fphar.2021.760671","volume":"12","author":"J Reckweg","year":"2021","unstructured":"Reckweg J, Mason NL, van Leeuwen C et al (2021) A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharmacol 12:760671. https:\/\/doi.org\/10.3389\/fphar.2021.760671","journal-title":"Front Pharmacol"},{"key":"6123_CR129","doi-asserted-by":"crossref","unstructured":"Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA et al (2012) High doses of extromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology 223(1):1\u201315","DOI":"10.1007\/s00213-012-2680-6"},{"key":"6123_CR130","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0306-4603(81)90003-4","volume":"6","author":"DJ Rohsenow","year":"1981","unstructured":"Rohsenow DJ, Marlatt GA (1981) The balanced placebo design: methodological considerations. Addict Behav 6:107\u2013122. https:\/\/doi.org\/10.1016\/0306-4603(81)90003-4","journal-title":"Addict Behav"},{"key":"6123_CR131","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.copsyc.2018.12.022","volume":"28","author":"MA Rosenkranz","year":"2019","unstructured":"Rosenkranz MA, Dunne JD, Davidson RJ (2019) The next generation of mindfulness-based intervention research: what have we learned and where are we headed? Curr Opin Psychol 28:179\u2013183. https:\/\/doi.org\/10.1016\/j.copsyc.2018.12.022","journal-title":"Curr Opin Psychol"},{"key":"6123_CR132","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1037\/h0044068","volume":"53","author":"D Rosenthal","year":"1956","unstructured":"Rosenthal D, Frank JD (1956) Psychotherapy and the placebo effect. Psychol Bull 53:294\u2013302. https:\/\/doi.org\/10.1037\/h0044068","journal-title":"Psychol Bull"},{"key":"6123_CR133","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30:1165\u20131180. https:\/\/doi.org\/10.1177\/0269881116675512","journal-title":"J Psychopharmacol"},{"key":"6123_CR134","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/1094428117698745","volume":"20","author":"TJ Roulet","year":"2017","unstructured":"Roulet TJ, Gill MJ, Stenger S, Gill DJ (2017) Reconsidering the value of covert research: the role of ambiguous consent in participant observation. Organ Res Methods 20:487\u2013517. https:\/\/doi.org\/10.1177\/1094428117698745","journal-title":"Organ Res Methods"},{"key":"6123_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1037\/cns0000119","volume":"4","author":"SL Russ","year":"2017","unstructured":"Russ SL, Elliott MS (2017) Antecedents of mystical experience and dread in intensive meditation. Psych Conscious Theory Res Prac 4:38\u201353. https:\/\/doi.org\/10.1037\/cns0000119","journal-title":"Psych Conscious Theory Res Prac"},{"key":"6123_CR136","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1176\/appi.ajp.2012.12040474","volume":"170","author":"BR Rutherford","year":"2013","unstructured":"Rutherford BR, Roose SP (2013) A model of placebo response in antidepressant clinical trials. Amer J Psych 170:723\u2013733. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12040474","journal-title":"Amer J Psych"},{"key":"6123_CR137","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1745-6916.2007.00050.x","volume":"2","author":"M Rutter","year":"2007","unstructured":"Rutter M (2007) Proceeding from observed correlation to causal inference: the use of natural experiments. Perspect Psychol Sci 2:377\u2013395. https:\/\/doi.org\/10.1111\/j.1745-6916.2007.00050.x","journal-title":"Perspect Psychol Sci"},{"key":"6123_CR138","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ije\/dym088","volume":"36","author":"DL Sackett","year":"2007","unstructured":"Sackett DL (2007) Commentary: measuring the success of blinding in RCTs: don\u2019t, must, can\u2019t or needn\u2019t? Int J Epidemiol 36:664\u2013665. https:\/\/doi.org\/10.1093\/ije\/dym088","journal-title":"Int J Epidemiol"},{"key":"6123_CR139","doi-asserted-by":"publisher","unstructured":"Schenberg EE (2021) Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Exp Rev Clin Pharm. https:\/\/doi.org\/10.1080\/17512433.2021.1951473","DOI":"10.1080\/17512433.2021.1951473"},{"key":"6123_CR140","doi-asserted-by":"publisher","unstructured":"Scott AJ, Sharpe L, Colagiuri B (2022) A systematic review and meta-analysis of the success of blinding in antidepressant RCTs. Psychiatry Res 114297. https:\/\/doi.org\/10.1016\/j.psychres.2021.114297","DOI":"10.1016\/j.psychres.2021.114297"},{"key":"6123_CR141","doi-asserted-by":"publisher","unstructured":"Scott AJ, Sharpe L, Quinn V et al (2021) Association of single-blind placebo run-in periods with the placebo response in randomized clinical trials of antidepressants: a systematic review and meta-analysis. JAMA Psychiatry. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.3204","DOI":"10.1001\/jamapsychiatry.2021.3204"},{"key":"6123_CR142","doi-asserted-by":"crossref","unstructured":"Sedgwick P, Greenwood N (2015) Understanding the Hawthorne effect. Brit Med J 351","DOI":"10.1136\/bmj.h4672"},{"key":"6123_CR143","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/02791072.2014.877322","volume":"46","author":"B Sessa","year":"2014","unstructured":"Sessa B (2014) Why psychiatry needs psychedelics and psychedelics need psychiatry. J Psychoactive Drugs 46:57\u201362. https:\/\/doi.org\/10.1080\/02791072.2014.877322","journal-title":"J Psychoactive Drugs"},{"key":"6123_CR144","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1097\/BRS.0b013e3181c2a8d3","volume":"35","author":"KJ Sherman","year":"2010","unstructured":"Sherman KJ, Cherkin DC, Ichikawa L et al (2010) Treatment expectations and preferences as predictors of outcome of acupuncture for chronic back pain. Spine 35:1471\u20131477. https:\/\/doi.org\/10.1097\/BRS.0b013e3181c2a8d3","journal-title":"Spine"},{"key":"6123_CR145","doi-asserted-by":"publisher","unstructured":"Siegel AN, Meshkat S, Benitah K, Lipsitz O et al (2021) Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.05.019","DOI":"10.1016\/j.jpsychires.2021.05.019"},{"key":"6123_CR146","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00406-019-00978-2","volume":"269","author":"N Solowij","year":"2019","unstructured":"Solowij N, Broyd S, Greenwood LM et al (2019) A randomised controlled trial of vaporised \u0394 9-tetrahydrocannabinol and cannabidiol alone and in combination in frequent and infrequent cannabis users: acute intoxication effects. Eur Arch Psychiatry Clin Neurosci 269:17\u201335","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6123_CR147","doi-asserted-by":"publisher","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","volume":"27","author":"RG Smart","year":"1966","unstructured":"Smart RG, Storm T, Baker EF, Solursh L (1966) A controlled study of lysergide in the treatment of alcoholism. I. The effects on drinking behavior. Q J Stud Alc 27:469\u2013482","journal-title":"Q J Stud Alc"},{"key":"6123_CR148","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jpain.2017.02.429","volume":"18","author":"SM Smith","year":"2017","unstructured":"Smith SM, Dworkin RH, Turk DC et al (2017) The potential role of sensory testing, skin biopsy, and functional brain imaging as biomarkers in chronic pain clinical trials: IMMPACT considerations. J Pain 18:757\u2013777. https:\/\/doi.org\/10.1016\/j.jpain.2017.02.429","journal-title":"J Pain"},{"key":"6123_CR149","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1097\/j.pain.0000000000001952","volume":"161","author":"SM Smith","year":"2020","unstructured":"Smith SM, Dworkin RH, Turk DC et al (2020) Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain 161:2446\u20132461. https:\/\/doi.org\/10.1097\/j.pain.0000000000001952","journal-title":"Pain"},{"key":"6123_CR150","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/medethics-2020-106070","volume":"47","author":"WR Smith","year":"2021","unstructured":"Smith WR, Sisti D (2021) Ethics and ego dissolution: the case of psilocybin. J Med Ethics 47:807\u2013814. https:\/\/doi.org\/10.1136\/medethics-2020-106070","journal-title":"J Med Ethics"},{"key":"6123_CR151","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5:463. https:\/\/doi.org\/10.1097\/COH.0b013e32833ed177","journal-title":"Curr Opin HIV AIDS"},{"key":"6123_CR152","doi-asserted-by":"publisher","first-page":"e62878","DOI":"10.7554\/eLife.62878","volume":"10","author":"B Szigeti","year":"2021","unstructured":"Szigeti B, Kartner L, Blemings A et al (2021) Self-blinding citizen science to explore psychedelic microdosing. Elife 10:e62878. https:\/\/doi.org\/10.7554\/eLife.62878","journal-title":"Elife"},{"key":"6123_CR153","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s10591-012-9201-y","volume":"34","author":"RB Tambling","year":"2012","unstructured":"Tambling RB (2012) A literature review of therapeutic expectancy effects. Contemp Fam Ther 34:402\u2013415. https:\/\/doi.org\/10.1007\/s10591-012-9201-y","journal-title":"Contemp Fam Ther"},{"key":"6123_CR154","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1177\/1740774507081217","volume":"4","author":"RN Tamura","year":"2007","unstructured":"Tamura RN, Huang X (2007) An examination of the efficiency of the sequential parallel design in psychiatric clinical trials. Clin Trials 4:309\u2013317. https:\/\/doi.org\/10.1177\/1740774507081217","journal-title":"Clin Trials"},{"key":"6123_CR155","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1017\/S0033291718003896","volume":"49","author":"A Thapar","year":"2019","unstructured":"Thapar A, Rutter M (2019) Do natural experiments have an important future in the study of mental disorders? Psychol Med 49:1079\u20131088. https:\/\/doi.org\/10.1017\/S0033291718003896","journal-title":"Psychol Med"},{"key":"6123_CR156","doi-asserted-by":"crossref","unstructured":"Timmermann C, Kettner H, Letheby C, Roseman L, Rosas F, Carhart-Harris R (2021) Psychedelics alter metaphysical beliefs. 10.31234\/osf.io\/f6sjk","DOI":"10.31234\/osf.io\/f6sjk"},{"key":"6123_CR157","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1001\/jama.1994.03510440069036","volume":"271","author":"JA Turner","year":"1994","unstructured":"Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE (1994) The importance of placebo effects in pain treatment and research. J Amer Med Assoc 271:1609\u20131614. https:\/\/doi.org\/10.1001\/jama.1994.03510440069036","journal-title":"J Amer Med Assoc"},{"key":"6123_CR158","volume-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","author":"US Food and Drug Administration","year":"2009","unstructured":"US Food and Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD"},{"key":"6123_CR159","volume-title":"Guidance for industry and FDA staff","author":"US Food and Drug Administration","year":"2020","unstructured":"US Food and Drug Administration (2020) Guidance for industry and FDA staff. Qualification Process for Drug Development Tools, Available at: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM230597.pdf"},{"key":"6123_CR160","doi-asserted-by":"publisher","unstructured":"Uthaug MV, Mason NL, Toennes SW et al (2021) A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. Psychopharm. https:\/\/doi.org\/10.1007\/s00213-021-05817-8","DOI":"10.1007\/s00213-021-05817-8"},{"key":"6123_CR161","doi-asserted-by":"publisher","unstructured":"van Elk M, Fejer G, Lempe P, Prochazckova L, Kuchar M, Hajkova K, Marschall J (2021) Effects of psilocybin microdosing on awe and aesthetic experiences: a preregistered field and lab-based study. Psychopharm 1\u201316. https:\/\/doi.org\/10.1007\/s00213-021-05857-0","DOI":"10.1007\/s00213-021-05857-0"},{"key":"6123_CR162","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/j.bja.2019.01.040","volume":"12","author":"L Vase","year":"2019","unstructured":"Vase L, Wartolowska K (2019) Pain, placebo, and test of treatment efficacy: a narrative review. Brit J Anaes 12:e254\u2013e262. https:\/\/doi.org\/10.1016\/j.bja.2019.01.040","journal-title":"Brit J Anaes"},{"key":"6123_CR163","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1080\/10503307.2016.1218089","volume":"28","author":"A V\u00eesl\u0103","year":"2018","unstructured":"V\u00eesl\u0103 A, Constantino MJ, Newkirk K, Ogrodniczuk JS, S\u00f6chting I (2018) The relation between outcome expectation, therapeutic alliance and outcome among depressed patients in group cognitive-behavioral therapy. Psychother Res 28:446\u2013456. https:\/\/doi.org\/10.1080\/10503307.2016.1218089","journal-title":"Psychother Res"},{"key":"6123_CR164","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1037\/cns0000045","volume":"3","author":"BE Wampold","year":"2016","unstructured":"Wampold BE, Frost ND, Yulish NE (2016) Placebo effects in psychotherapy: a flawed concept and a contorted history. Psych Consc Theory Res Prac 3:108\u2013120. https:\/\/doi.org\/10.1037\/cns0000045","journal-title":"Psych Consc Theory Res Prac"},{"key":"6123_CR165","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1037\/a0018912","volume":"78","author":"CA Webb","year":"2010","unstructured":"Webb CA, DeRubeis RJ, Barber JP (2010) Therapist adherence\/competence and treatment outcome: a meta-analytic review. J Consult Clin Psychol 78:200\u2013211. https:\/\/doi.org\/10.1037\/a0018912","journal-title":"J Consult Clin Psychol"},{"key":"6123_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-84746-0","volume":"11","author":"B Weiss","year":"2021","unstructured":"Weiss B, Miller JD, Carter NT, Campbell WK (2021) Examining changes in personality following shamanic ceremonial use of ayahuasca. Sci Rep 11:1\u201315. https:\/\/doi.org\/10.1038\/s41598-021-84746-0","journal-title":"Sci Rep"},{"key":"6123_CR167","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0304-3959(92)90032-7","volume":"50","author":"CW Whitney","year":"1992","unstructured":"Whitney CW, Von Korff M (1992) Regression to the mean in treated versus untreated chronic pain. Pain 50:281\u2013285. https:\/\/doi.org\/10.1016\/0304-3959(92)90032-7","journal-title":"Pain"},{"key":"6123_CR168","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, Lyons DM, Schatzberg AF (2019) Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry 24:1779\u20131786. https:\/\/doi.org\/10.1038\/s41380-019-0503-4","journal-title":"Mol Psychiatry"},{"key":"6123_CR169","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175:1205\u20131215. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18020138","journal-title":"Am J Psychiatry"},{"key":"6123_CR170","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1556\/2054.2019.032","volume":"4","author":"MT Williams","year":"2020","unstructured":"Williams MT, Labate BC (2020) Diversity, equity, and access in psychedelic medicine. J Psychedelic Stud 4:1\u20133. https:\/\/doi.org\/10.1556\/2054.2019.032","journal-title":"J Psychedelic Stud"},{"key":"6123_CR171","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0016","volume":"1","author":"B Wilsey","year":"2016","unstructured":"Wilsey B, Deutsch R, Marcotte TD (2016) Maintenance of blinding in clinical trials and the implications for studying analgesia using cannabinoids. Cannabis Cannabinoid Res 1:139\u2013148. https:\/\/doi.org\/10.1089\/can.2016.0016","journal-title":"Cannabis Cannabinoid Res"},{"key":"6123_CR172","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"PE Wolfson","year":"2020","unstructured":"Wolfson PE, Andries J, Feduccia AA et al (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep 10:1\u201315. https:\/\/doi.org\/10.1038\/s41598-020-75706-1","journal-title":"Sci Rep"},{"key":"6123_CR173","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2020","unstructured":"Yaden DB, Griffiths RR (2020) The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharm Trans Sci 4:568\u2013572. https:\/\/doi.org\/10.1021\/acsptsci.0c00194","journal-title":"ACS Pharm Trans Sci"},{"key":"6123_CR174","doi-asserted-by":"publisher","first-page":"108071","DOI":"10.1016\/j.drugalcdep.2020.108071","volume":"212","author":"RA Yockey","year":"2020","unstructured":"Yockey RA, Vidourek RA, King KA (2020) Trends in LSD use among US adults: 2015\u20132018. Drug Alcohol Depend 212:108071. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108071","journal-title":"Drug Alcohol Depend"},{"key":"6123_CR175","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12564-014-9320-2","volume":"15","author":"SK Yoo","year":"2014","unstructured":"Yoo SK, Hong S, Sohn N, O\u2019Brien KM (2014) Working alliance as a mediator and moderator between expectations for counseling success and counseling outcome among Korean clients. Asia Pac Educ Rev 15:271\u2013281. https:\/\/doi.org\/10.1007\/s12564-014-9320-2","journal-title":"Asia Pac Educ Rev"},{"key":"6123_CR176","doi-asserted-by":"publisher","unstructured":"Yoon G, Petrakis IL, Krystal JH (2019) Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psych 76:337\u2013338. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3990","DOI":"10.1001\/jamapsychiatry.2018.3990"},{"key":"6123_CR177","doi-asserted-by":"crossref","unstructured":"Younger J, Gandhi V, Hubbard E, Mackey S (2012) Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clinical Trials 9(6):767\u2013776","DOI":"10.1177\/1740774512465064"},{"key":"6123_CR178","doi-asserted-by":"publisher","unstructured":"Zhipei ZHU, Zhang L, Jiang J et al (2014) Comparison of psychological placebo and waiting list control conditions in the assessment of cognitive behavioral therapy for the treatment of generalized anxiety disorder: a meta-analysis. Shanghai Arch Psychiatry 26(319). https:\/\/doi.org\/10.11919\/j.issn.1002-0829.214173","DOI":"10.11919\/j.issn.1002-0829.214173"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06123-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06123-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06123-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T02:10:18Z","timestamp":1654222218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06123-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":178,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["6123"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06123-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.31234\/osf.io\/nrb3t","asserted-by":"object"}]},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JDW was a paid consultant for Silo Pharma and Filament Health last in June 2021. BDH is a paid consultant for Clairvoyant Therapeutics. None of the other co-authors have any conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}